460-07-1

Basic information

• Product Name: N-ACETYLETHYLENEIMINE
• Synonyms: 1-acetyl-aziridin;1-acetylaziridine;acetylethyleneimine;N-ACETYLETHYLENEIMINE;AEI;1-aziridin-1-ylethanone;N,N-ethylideneacetamide;N-Acetylethylenimine
• CAS NO: 460-07-1
• Molecular Formula: C₄H₇NO
• Molecular Weight: 85.1
• EINECS: 207-301-8
• Product Categories: Miscellaneous Reagents;Heterocycles
• Mol File: 460-07-1.mol

Chemical Properties

• Melting Point: 161 °C
• Boiling Point: 44-45°C
• Flash Point: 76.2°C
• Appearance: /
• Density: 1.0408 (rough estimate)
• Vapor Pressure: 1.22mmHg at 25°C
• Refractive Index: 1.4340 (estimate)
• Storage Temp.: -20?C Freezer
• PKA: -2.36±0.20(Predicted)
• Stability: Store in Freezer
• CAS DataBase Reference: N-ACETYLETHYLENEIMINE(CAS DataBase Reference)
• NIST Chemistry Reference: N-ACETYLETHYLENEIMINE(460-07-1)
• EPA Substance Registry System: N-ACETYLETHYLENEIMINE(460-07-1)

Safety Data

• Hazardous Substances Data: 460-07-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-Acetylethyleneimine is used as a virus inactivator for the preparation of virus vaccines, specifically for foot-and-mouth disease virus (FMDV) and poliovirus. The inactivation process using AEI does not affect the biological properties of several proteins, ensuring that the viral proteins involved in the attachment and uncoating process remain unaffected. This allows for the development of vaccines that are both safe and effective in preventing viral infections.

Safety Profile

Poison by intraperitoneal route. Questionable carcinogen with experimental tumorigenic and neoplastigenic data. When heated to decomposition it emits toxic fumes of NOx,.

InChI:InChI=1/C4H7NO/c1-4(6)5-2-3-5/h2-3H2,1H3

Upstream product

• 151-56-4 ethyleneimine 
• 463-51-4 Ketene 
• 75-36-5 acetyl chloride 

Downstream Products

• 1190-73-4 2-(acetylamino)ethanethiol 
• 92349-49-0 bis(2-acetylaminoethyl) sulfide 
• 69622-45-3 o-(acetylmethyl)phenyl isocyanide 
• 126377-36-4 N-<2-<<2-(1H-imidazol-4-yl)ethyl>(phenylmethyl)amino>ethyl>acetamide 

Relevant articles and documents

Novel compounds and methods for synthesis and therapy

Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

CARBOCYCLIC COMPOUNDS

Novel carbocyclic compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

Compounds and methods for synthesis and therapy

Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

CARBOCYCLIC COMPOUNDS

Novel carbocyclic compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

THE PHOTOINDUCED RING-OPENING REACTION OF 1-(2-NAPHTHOYL)AZIRIDINE IN ALCOHOLS

Photorecation of 1-(2-naphthoyl)aziridine (1) in a series of alcohols have been studied at λex. 313 nm and room temperature under deaerated conditions.Irradiation of (1) in methanol gave N-(2- methoxyethyl)naphthalene-2-carboxamide (2a) selectively, whily N-ethylnaphthalene-2-carboxamide (3) was produced in ethanol and propan-2-ol.The competitive formation of N-(2-t-butoxyethyl)-naphthalene-2-carboxamide (2b) and (3) occurred in t-butyl alcohol.These alcohols formed 1:1 hydrogen bonds with (1) in their ground states.The quantum yield for the fluorwescens emission (ΦF) of (1) increased and the red shift of the emission maximum was enhanced with the increase in hydrogen bonding ability of the alcohols.Penta-1,3-diene quenched the formation of (3) but not (2a) or (2b).The Stern-Volmer plot for quenching of the formation of (3) by penta-1,3-diene was linear in propan-2-ol, whereas it curved downward to approach a definite value in ethanol or t-butyl alcohol.The quantum yield of (2b) in t-butyl alcohol-containing mixed solvents tended to increase with the increased dielectric constant (ε).